This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia
Male of age 18-50 years
Clinical Diagnosis of Androgenetic Alopecia
Written informed consent
Other types of Alopecia or other diseases that can cause hair loss
Clinically significant scalp disease such as seborrheic dermatitis or psoriasis
Clinically significant hepatic disease, thyroid disease, or mental illness, as determined by the Investigator
Participants who do not agree to use contraception during the trial and for 24 weeks after the last dose, and plan to provide sperm or conceive within 24 weeks after the last dose